David Hutton

ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.

Bausch + Lomb's Yolande Barnard, shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.

Investigators from the University of Maryland found that uncovering the mechanism of vision loss in Usher syndrome yields additional drug targets for eventual development of better therapies.

Unity Biotechnology announces improvement in visual acuity sustained through 24 weeks following single dose of UBX1325 in Phase 1 study of patients with advanced vascular eye disease.

Alcon this week announced its plans to acquire glaucoma surgery device maker Ivantis Inc. in a $475 million deal.

Michael Rivers, MD, director of ophthalmology, Modernizing Medicine, shares what lingers on his mind in the field of ophthalmology at the end of the day.

Organizations are urging consumers to be aware of insurance policies that can limit their access to sight-saving procedures and treatments.

Aldeyra Therapeutics announced today that it has achieved the primary endpoint of ocular redness in its randomly assigned, double-masked, vehicle-controlled Phase 2 clinical trial in dry eye disease.

Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia.

Investigators in Australia are developing a new rapid screening test for glaucoma that could help advance early detection of the disease.

The Cleveland Clinic named Rishi Singh, MD, president of the Cleveland Clinic Martin North and South hospitals in Martin County, Florida.

Two photographs are selected by an independent panel of five judges for this year’s honors.

The Academy's annual meeting set for November 12 to 15 in New Orleans.

According to investigators, the risk of death from strokes, heart attacks and other vascular causes is increased by more than a third.

According to the company, Susvimo is a first-of-its-kind therapeutic approach for wet AMD and may help people with the disease maintain their vision with as few as two treatments per year.

A coalition of vision groups held a briefing on Capitol Hill this week to educate legislators on increasing incidence of myopia and the associated cost burden.

Fellowship recipient Christopher J. Kaler will explore functional links between BAP1 loss and aberrant activity of the nucleosome remodeling and deacetylase complex, which normally mediates embryonic lineage commitment and cellular differentiation.

JD Schaub, chief operating officer at RVL Pharmaceuticals, shares what lingers on his mind in the ophthalmic field at the end of the day.

In a study, investigators demonstrated the safety and therapeutic potential of clinically compliant iPSC-derived photoreceptor precursors as a cell replacement source for future clinical trials.

Longtime clinician, researcher and head of the Ophthalmology Department at UCSF will succeed David W. Parke II, MD, at Academy helm.

Ocular herpes infection is a leading cause of infectious blindness and can lead to lethal brain infections. Using genetically modified mice models, investigators uncovered the importance of mTORC2 in activation of innate- and virus-adaptive immunity during ocular HSV-1 infection.

As the world comes together to shine a global spotlight on blindness and vision impairment on World Sight Day, several global organizations and companies are stepping up to increase awareness of eye health, including the importance of regular examinations by an ophthalmologist or optometrist.

Ophthalmologists and industry executives share what lingers on their minds at the end of the day.

Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.

Alcon's Paul Hallen offers a look at the highlights from the 2021 ASRS annual meeting's OIS panel as well as the company's latest innovations.

According to 4D Molecular Therapeutics, it has received FDA Clearance of an IND Application for 4D-150, a dual-transgene intravitreal gene therapy for patients with wet AMD.

The company will move the highest dose of THR-149 (0.13mg) into Part B of the study based on favorable safety profile and positive efficacy data.

The American Society of Retina Specialists (ASRS) will host its 39th Annual Scientific Meeting from October 8-12, 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.

Investigators found evidence of improvement in vision and retinal structure in patients with DME and AMD sustained through 12 weeks.

A team of investigators at the Texas Tech University Health Sciences Center have developed a technology derived from corneal epithelial stem cells to improve outcomes for DED patients.